RTP Mobile Logo
Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Challenging Cases of ER-Positive and Triple-Negative Breast Cancer (Webinar Audio Proceedings)
Released July 2021

Featuring perspectives from Drs Matthew P Goetz, Hope S Rugo and Melinda Telli. (Audio Program)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

    LEARNING OBJECTIVES

    • Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize adjuvant systemic therapy for individuals with newly diagnosed ER-positive, HER2-negative breast cancer.
    • Individualize the selection and sequence of systemic therapy for patients with ER-positive metastatic breast cancer, considering age, menopausal status, prior treatment course, comorbidities, symptomatology and extent of disease.
    • Develop an evidence-based algorithm for the treatment of advanced hormone receptor-positive pre- and postmenopausal breast cancer, incorporating endocrine therapy and biologic and chemotherapeutic agents.
    • Understand the biologic rationale for and available data with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the potential therapeutic role of these agents in this setting.
    • Recognize the FDA approval of and published safety data with the PI3 kinase inhibitor alpelisib in combination with fulvestrant for patients with advanced HER2-negative breast cancer harboring a PIK3CA mutation.
    • Appraise available data with (neo)adjuvant PARP inhibitors for patients with BRCA mutations and HER2-negative breast cancer, and consider the current and potential role of these agents in clinical decision-making.
    • Appreciate recent FDA approvals of and ongoing clinical research evaluating novel agents and strategies for ER-positive or triple-negative breast cancer, and counsel patients regarding protocol and nonresearch treatment recommendations.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Matthew P Goetz, MD
    Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD
    Professor of Oncology and Pharmacology
    Director, Mayo Clinic Breast SPORE
    Co-Leader, Women’s Cancer Program
    Mayo Clinic
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Consulting Agreement: Samsung Bioepis (limited consulting); Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seagen Inc, Sermonix Pharmaceuticals; Honoraria: Mylan, Puma Biotechnology Inc; Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan, Novartis, Pfizer Inc.

    Melinda Telli, MD
    Associate Professor of Medicine
    Stanford University School of Medicine
    Director, Breast Cancer Program
    Stanford Cancer Institute
    Stanford, California

    Advisory Committee: AbbVie Inc, Blueprint Medicines, Celgene Corporation, Chinook Therapeutics, Daiichi Sankyo Inc, Immunomedics Inc, Lilly, Natera Inc, OncoSec Medical, Pfizer Inc; Consulting Agreements: Genentech, a member of the Roche Group, Guardant Health, Merck; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biothera Pharmaceuticals Inc, Calithera Biosciences, EMD Serono Inc, Genentech, a member of the Roche Group, Merck, OncoSec Medical, Pfizer Inc, PharmaMar, Tesaro, A GSK Company, Vertex Pharmaceuticals Incorporated; Data and Safety Monitoring Board/Committee: G1 Therapeutics, Immunomedics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences, Lilly, Merck, Novartis, Puma Biotechnology Inc and Seagen Inc.

    Release date: July 2021
    Expiration date: July 2022

Acknowledge and close

Listen to program
(WIFI is recommended for best performance):